Literature DB >> 28223886

Updates on Treatment of Ebola Virus Disease.

Lakshmi Krishnasamy1, Chitralekha Saikumar2.   

Abstract

Ebola viral disease is one of the major threats world wide. But the treatment option is merely supportive and symptomatic therapy. Vaccination and drug therapies are still under trial. This article throws light into the various emerging treatment options for the Ebola viral disease.

Entities:  

Keywords:  Ebola virus; drug therapy; reconvalescent plasma; treatment; vaccine

Year:  2015        PMID： 28223886      PMCID： PMC5295760     

Source DB:  PubMed          Journal:  Malays J Med Sci        ISSN： 1394-195X


  35 in total

1.  A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.

Authors:  J E Ledgerwood; P Costner; N Desai; L Holman; M E Enama; G Yamshchikov; S Mulangu; Z Hu; C A Andrews; R A Sheets; R A Koup; M Roederer; R Bailer; J R Mascola; M G Pau; N J Sullivan; J Goudsmit; G J Nabel; B S Graham
Journal:  Vaccine       Date:  2010-10-27       Impact factor: 3.641

2.  A practical treatment for patients with Ebola virus disease.

Authors:  David S Fedson
Journal:  J Infect Dis       Date:  2014-08-25       Impact factor: 5.226

3.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.

Authors:  Thomas W Geisbert; Lisa E Hensley; Peter B Jahrling; Tom Larsen; Joan B Geisbert; Jason Paragas; Howard A Young; Terry M Fredeking; William E Rote; George P Vlasuk
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

4.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

Authors:  Kelly L Warfield; Dana L Swenson; Gene G Olinger; Warren V Kalina; M Javad Aman; Sina Bavari
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

5.  DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge.

Authors:  L Vanderzanden; M Bray; D Fuller; T Roberts; D Custer; K Spik; P Jahrling; J Huggins; A Schmaljohn; C Schmaljohn
Journal:  Virology       Date:  1998-06-20       Impact factor: 3.616

6.  Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells.

Authors:  Mangala Rao; Mike Bray; Carl R Alving; Peter Jahrling; Gary R Matyas
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Evaluation in nonhuman primates of vaccines against Ebola virus.

Authors:  Thomas W Geisbert; Peter Pushko; Kevin Anderson; Jonathan Smith; Kelly J Davis; Peter B Jahrling
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

8.  Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study.

Authors:  Thomas W Geisbert; Amy C H Lee; Marjorie Robbins; Joan B Geisbert; Anna N Honko; Vandana Sood; Joshua C Johnson; Susan de Jong; Iran Tavakoli; Adam Judge; Lisa E Hensley; Ian Maclachlan
Journal:  Lancet       Date:  2010-05-29       Impact factor: 79.321

9.  A systematic screen of FDA-approved drugs for inhibitors of biological threat agents.

Authors:  Peter B Madrid; Sidharth Chopra; Ian D Manger; Lynne Gilfillan; Tiffany R Keepers; Amy C Shurtleff; Carol E Green; Lalitha V Iyer; Holli Hutcheson Dilks; Robert A Davey; Andrey A Kolokoltsov; Ricardo Carrion; Jean L Patterson; Sina Bavari; Rekha G Panchal; Travis K Warren; Jay B Wells; Walter H Moos; Raelyn L Burke; Mary J Tanga
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

10.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.